Ruti Aga's six-year ban: the fake prescription cost more than the medicine

A clinic that does not exist. A signatory who is a family member, with no medical registration. An old prescription pad taken from a former workplace whose employer confirms the person never set foot there. That was the entire medical file Ruti Aga produced to explain her positive test.

The Athletics Integrity Unit (AIU), World Athletics' independent integrity body, walked through every link in that story. The clinic denied the prescription. The professional registry confirmed no such name. The signatory admitted the family relationship. The tampering finding was established, and the sanction handed to the 2026 Tokyo Marathon champion was six years of ineligibility, running from 10 September.

Most Vietnamese-language reports translated the substance in this case as a "steroid" or a "performance enhancer." Methylprednisolone is a synthetic glucocorticoid, a corticosteroid, sitting in WADA class S9, prohibited in-competition only, and classed as a "Specified Substance" — the category anti-doping law accepts as plausibly linked to therapeutic or inadvertent use. That mistranslation is no small matter. It changes how the entire sanction should be read.

The baseline sanction for presence of a prohibited substance is four years. For a Specified Substance, where intent to enhance performance cannot be proven, the starting point drops to two years. Aga received two years for the substance and four years for the falsification. The WADA Code requires multiple violations to be served consecutively, not concurrently. Two plus four equals six.

The expensive part of this sanction is not the dose but the piece of paper meant to prove the dose was properly prescribed. The penalty for the cover-up is double the penalty for the underlying violation — and that is the entire governance lesson of the case.

The case needs to be placed correctly on the road. Aga is not a fringe name promoted to fill a start list. She won the 2026 Tokyo Marathon and finished runner-up at three World Marathon Majors — a record that places her among the elite of women's road running across 2026–2026. A record is only an excuse to remember a person rather than a number; here, though, the number matters, because it fixes the scale of the loss.

Based on my experience covering races, I still keep the habit of writing out athlete name pronunciations before every broadcast. "Ruti Aga" is a name I drilled from the 2026 season, after mispronouncing a Central American athlete's name three times in the first half and having to rewatch an entire tournament to fix it. I learned that a name is the first door of respect — and once that door opens correctly, people will read what lies behind it.

The triggering result was a half marathon win in China in March. The source does not disclose the mark, so any inference about the sporting significance of that course is speculation. The context, however, is clear: this is the template of an appearance-fee race, where East African distance runners are invited for attractive fees and tested at far lower density than at World Marathon Majors. The result there is almost certainly annulled, along with the prize money.

At 32, Aga was at the top of her earning window. A six-year ban returns her at roughly 38, after a layoff from which no women's marathoner has come back to World Marathon Majors podium level. Competitively, this is a career-ending sanction, not a suspended one.

But the story is being told in the wrong place. It is framed as a doping case, when it is closer to a collapse of the medical support system around an athlete. If the knee injury Aga cited was genuine — and a corticosteroid is an entirely reasonable treatment for a joint injury — then an intra-articular injection covered by a valid Therapeutic Use Exemption might have produced no case at all, or a reduced one. What turned a therapeutic misadventure into six years was the reflex to cover it up. And that reflex rarely comes from an athlete alone.

This is the case of a thin support apparatus, not of a sophisticated doping operation. A relative playing doctor, a borrowed prescription pad, a fictitious clinic — the amateurism is itself diagnostic: nobody around this athlete was doing professional compliance work.

An athlete with private counsel and an integrity adviser takes the correct route: honest disclosure, a retroactive TUE application, and a light sanction. An athlete inside the East African road-running pipeline, where legal support barely exists, takes the route of forged documents — and the AIU needed only a few phone calls to collapse the whole structure. The AIU's verification practice now includes direct clinic confirmation and registration checks; forged paperwork is no longer a hiding place.

One point needs blocking before it becomes a headline: this case is not evidence of a state doping system. Ethiopia's marathon depth is so great that one individual's absence barely shifts the women's road landscape. Aga is a mesh in that net, not an anchor. The real damage is to the commercial credibility of the Ethiopian road-running brand — genuinely valuable to agents, race organisers and sponsors — not to the results board.

I once thought I came to commentate on races; it turned out I came to listen to people. The Aga case adds another layer to the job: listen also to what people do not say, and verify the documents they produce in order to stay silent.

Something outlasts titles: the way people remember how you played. For Aga, what people will remember is not the sprint in Tokyo in spring 2026, but a clinic that never existed. The question left for athletics is not whether six years is heavy, but how many other athletes are walking into a back room with an old prescription pad and no one to ask.